Suraj S. Nongmaithem

Suraj S. Nongmaithem

Auto-generated profile, based on publicly available information

Suraj S. Nongmaithem

Genomic Research on Complex Diseases Group (GRC-Group), CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
PIPrachand Issarapu
Prachand Issarapu
MAManisha Arumalla
Manisha Arumalla
HEHannah R. Elliott
Hannah R. Elliott
SNSuraj S. Nongmaithem
Suraj S. Nongmaithem
ASAlagu Sankareswaran
Alagu Sankareswaran
SOStephen Owens
Stephen Owens
Human height is strongly influenced by genetics but the contribution of modifiable epigenetic factors is under-explored, particularly in low and middle-income countries (LMIC). We investigate links between blood DNA methylation and child height in four LMIC cohorts (n = 1927) and identify a robust association at three CpGs in the suppressor of cytokine signaling 3 (SOCS3) gene which replicates in a high-income country cohort (n = 879). SOCS3 methylation (SOCS3m)—height associations are independent of genetic effects. Mendelian randomization analysis confirms a causal effect of SOCS3m on height. In longitudinal analysis, SOCS3m explains a maximum 9.5% of height variance in mid-childhood while the variance explained by height polygenic risk score increases from birth to 21 years. Children’s SOCS3m is associated with prenatal maternal folate and socio-economic status. In-vitro characterization confirms a regulatory effect of SOCS3m on gene expression. Our findings suggest epigenetic modifications may play an important role in driving child height in LMIC.

18 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AVAjay Deepak Verma
Ajay Deepak Verma
SNSuraj S Nongmaithem
Suraj S Nongmaithem
CMChallapalli Mounika
Challapalli Mounika
SRSwetha Ramachandran
Swetha Ramachandran
AUAnushri Umesh
Anushri Umesh
GCGiriraj Ratan Chandak
Giriraj Ratan Chandak
Vitamin B12 (B12) is one of the key co-factors in One-Carbon Metabolism pathway, and its dysregulation is associated with various clinical conditions including congenital malformations, neural tube defects, and low birthweight, etc. However, the underlying molecular mechanism is scarcely studied. This study investigated the role of B12 in early embryonic development by generating a knockout of transcobalamin 2 ( tcn2 ), a B12 transporter in zebrafish. We generated tcn2 -/- zebrafish by creating premature stop codons in exon 7 and confirmed by qRT-PCR and immunoblotting. Phenotypic changes were captured, growth and survival assays were conducted at different developmental stages. B12 supplementation assay was conducted by rearing tcn2 -/- embryos in embryo-medium containing 10 µM cyanocobalamin. RNA-sequencing data was generated in triplicates in embryos at 1-cell and 24 hpf stages, with and without B12 supplementation. Genes with log 2 FC ≥ 0.6 and adjusted p-value ≤ 0.01 were considered differentially expressed genes (DEGs) and proceeded for functional annotation and enrichment analysis. The F1 tcn2 -/- embryos grew normally. However, the F2 tcn2 -/- embryos remained unhatched, showed delayed somitogenesis, curved or deformed tails, abnormal yolk extension, pericardial and yolk sac edema, etc. and ∼70% were dead by 4 dpf. The abnormalities were partially ameliorated by B12 supplementation throughout developmental stages. Transcriptome analysis identified DEGs enriched in pathways including spliceosome, ribosome biogenesis, branched-chain amino acid degradation, lysosome, iron homeostasis, metabolic and immune response pathways, etc. We observed dysregulated expression of many genes with epigenetic functions including sfswap , ctcf , mettl3 , alkbh5 , and hdac , etc., in the 1-cell tcn2 -/- embryos. Notably, B12 supplementation restored expression of many DEGs indicating a potential role of B12 in transcriptional regulation during embryonic development. Our study delineates the importance of B12 during embryonic development and provides interesting insights into the molecular mechanisms underlying the observed phenotypic changes.

26 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ASAlagu Sankareswaran
Alagu Sankareswaran
DLDimple Lavanuru
Dimple Lavanuru
BNBhanu Teja Nalluri
Bhanu Teja Nalluri
STShalbha Tiwari
Shalbha Tiwari
RNRashmi Nagaraj
Rashmi Nagaraj
GCGiriraj Ratan Chandak
Giriraj Ratan Chandak
Background: Genetic risk scores (GRS) for type 1 diabetes (T1D) have been developed primarily in European populations, limiting their generalisability across ancestries. Indians differ from Europeans in clinical characteristics of T1D and overall genetic architecture, yet systematic evaluation of T1D GRS performance in multi-regional Indian cohorts is lacking.Methods: The study included 597 T1D patients and 3347 non-diabetic controls from different regions in India. Genotyping, imputation, quality control analysis, and construction of the 67-SNPs T1D GRS were performed using standardised pipelines. Discriminative performance was assessed using Receiver Operative Curve-Area under Curve (ROC-AUC) analysis, and optimal thresholds were derived using Youden’s index. HLA-DQ diplotype frequencies were compared, and association analysis was conducted using multivariable logistic regression.Findings: T1D GRS showed consistent discriminative performance across Indian cohorts [ROC-AUC=0.84 (range=0·78-0·87)], supporting its comprehensive use for T1D classification in India. Notably, its performance was lower in islet cell autoantibody (IA) negative compared with IA positive T1D patients (ROC-AUC, 0·75 vs 0·85) and in adult-onset than in childhood-onset patients (0·74 vs 0·84). We observed a lower frequency of protective HLA-DQ diplotypes and a strong association of HLA-DQ81 containing diplotypes in childhood-onset T1D. Application of an India-specific T1D GRS score improved the sensitivity than the European cut-off.Interpretation: T1D GRS is a valuable unified diagnostic tool in Indians, but its performance varies by islet cell autoantibody status and age at onset, likely reflecting population-specific HLA architecture. European-derived T1D GRS thresholds under-classify the genetic risk, highlighting the importance of ancestry-aware optimisation in Indians.

23 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ASAlagu Sankareswaran
Alagu Sankareswaran
DLDimple Lavanuru
Dimple Lavanuru
BNBhanu Teja Nalluri
Bhanu Teja Nalluri
STShalbha Tiwari
Shalbha Tiwari
RNRashmi Nagaraj
Rashmi Nagaraj
GCGiriraj Ratan Chandak
Giriraj Ratan Chandak
Summary: Background: Genetic risk scores (GRS) for type 1 diabetes (T1D) have been developed primarily in European populations, limiting their generalisability across ancestries. Indians differ from Europeans in clinical characteristics of T1D and overall genetic architecture, yet systematic evaluation of T1D GRS performance in multi-regional Indian cohorts is lacking. Methods: The study included 597 T1D patients and 3347 non-diabetic controls from different regions in India. Genotyping, imputation, quality control analysis, and construction of the 67-SNPs T1D GRS were performed using standardised pipelines. Discriminative performance was assessed using Receiver Operative Curve-Area under Curve (ROC-AUC) analysis, and optimal thresholds were derived using Youden’s index. HLA-DQ diplotype frequencies were compared, and association analysis was conducted using multivariable logistic regression. Findings: T1D GRS showed consistent discriminative performance across Indian cohorts [ROC-AUC=0.84 (range=0·78-0·87)], supporting its comprehensive use for T1D classification in India. Notably, its performance was lower in islet cell autoantibody (IA) negative compared with IA positive T1D patients (ROC-AUC, 0·75 vs 0·85) and in adult-onset than in childhood-onset patients (0·74 vs 0·84). We observed a lower frequency of protective HLA-DQ diplotypes and a strong association of HLA-DQ81 containing diplotypes in childhood-onset T1D. Application of an India-specific T1D GRS score improved the sensitivity than the European cut-off. Interpretation: T1D GRS is a valuable unified diagnostic tool in Indians, but its performance varies by islet cell autoantibody status and age at onset, likely reflecting population-specific HLA architecture. European-derived T1D GRS thresholds under-classify the genetic risk, highlighting the importance of ancestry-aware optimisation in Indians. Funding: CDRC grant CDRC202111026 and CSIR Intramural Grant P50. Research in context: Evidence before this study: Previous studies have shown that a 67-SNPs T1D genetic risk score (GRS) can distinguish T1D patients from non-diabetic controls and other forms of diabetes, but its performance varies across ancestries. Islet cell autoantibodies (IA) have important diagnostic value for classifying type 1 diabetes (T1D). However, their prevalence in India varies widely, with up to one-quarter of patients testing negative, limiting their clinical utility. Evidence supporting the use of the T1D GRS in India, combined with IA antibodies status is limited to a single cohort representing one linguistic group. The applicability of T1D GRS across multi-centric clinical settings has not been systematically evaluated. Added value of this study: This study validates the 67-SNPs T1D GRS across multiple Indian cohorts representing major linguistic groups, supporting its use as a unified diagnostic tool. Differences in T1DGRS performance between childhood-and adult-onset T1D are linked to enrichment of protective HLA-DQ diplotypes in adult-onset disease, providing genetic insight into disease heterogeneity. The study also demonstrates that European-derived GRS thresholds systematically under-classify genetic risk in Indians and the population-specific threshold is essential. Implications of all the available evidence: The European-derived T1D GRS can be applied across Indian clinical settings with consistent discriminative performance. However, its utility is influenced by islet cell autoantibody status and the age at onset of disease. Ancestry-aware threshold optimisation substantially improves diagnostic accuracy and is essential for equitable implementation of T1D GRS in Indians. Larger studies are needed to identify population-specific risk variants and further refine genetic tools for clinical diagnosis.